Hang YU, Wensheng LIU, Ning ZHANG, et al. The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis[J]. China Oncology, 2022, 32(9): 794-799.
DOI:
Hang YU, Wensheng LIU, Ning ZHANG, et al. The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis[J]. China Oncology, 2022, 32(9): 794-799. DOI: 10.19401/j.cnki.1007-3639.2022.09.006.
The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis
按照实体瘤疗效评价标准(Response Evaluation Criteria in Solid Tumors
RECIST)1.1来评价疗效
分别计算其术后客观缓解率(objective response rate
ORR)、疾病控制率(disease control rate
DCR)及无进展生存期(progression-free survival
PFS)。术后不良反应分级采用常见不良事件评价标准(common terminology criteria for adverse events
CTCAE)v5.0。
结果:
按照RECIST 1.1来评价
ORR达到80.0%
DCR达到100.0%。10例患者中3例达到PFS
最长为25.0个月
其余患者尚未进展。不良反应主要为发热、肝区疼痛及肝功能一过性损伤等
对症处理后均可缓解
无严重术后并发症。
结论:
cNENLM十分罕见
TAE疗效佳
术后并发症可控。
Abstract
Background and Purpose:
Liver metastases are common in neuroendocrine neoplasm (NEN). C
ystic NEN liver metastases (cNENLM) are rare
and the efficacy of transarterial embolization (TAE) has not been reported. This study summarized and analyzed the efficacy and safety of TAE for cNENLM.
Methods:
From January 2016 to April 2022
10 patients with cNENLM were enrolled in this study among 440 patients under TAE treatment at The First Affiliated Hospital
Sun Yat-sen University and Fudan University Shanghai Cancer center. The efficacy was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Objective response rate (ORR)
disease control rate (DCR) and progression-free survival (PFS) were analyzed as well. The common terminology criteria for adverse events (CTCAE) v5.0 was applied to evaluate the adverse effects.
Results:
With 80.0% ORR and 100.0% DCR according to RECIST 1.1
3 cases achieved PFS. Among them
the longest one was 25.0 months. Disease progression was not observed in the remaining patients. The common complications were fever
hepatalgia and transient liver dysfunction
which could be alleviated by symptomatic treatment. No severe complication occurred.
Conclusion:
cNENLM are infrequent. TAE had significant curative effect on cNENLM
and complications were manageable.
关键词
Keywords
references
GOSAIN R , BALL S , RANA N , et al . Geographic and demographic features of neuroendocrine tumors in the United States of America: a population-based study [J ] . Cancer , 2020 , 126 ( 4 ): 792 - 799 . DOI: 10.1002/cncr.32607 http://doi.org/10.1002/cncr.32607
DASARI A , SHEN C , HALPERIN D , et al . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States [J ] . JAMA Oncol , 2017 , 3 ( 10 ): 1335 - 1342 . DOI: 10.1001/jamaoncol.2017.0589 http://doi.org/10.1001/jamaoncol.2017.0589
PAVEL M , O'TOOLE D , COSTA F , et al . ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 172 - 185 . DOI: 10.1159/000443167 http://doi.org/10.1159/000443167
RONOT M , CUCCIOLI F , DIOGUARDI BURGIO M , et al . Neuroendocrine liver metastases: vascular patterns on triple-phase MDCT are indicative of primary tumour location [J ] . Eur J Radiol , 2017 , 89 : 156 - 162 . DOI: S0720-048X(17)30051-7 http://doi.org/S0720-048X(17)30051-7
DEL PRETE M , DI SARNO A , MODICA R , et al . Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors [J ] . J Endocrinol Invest , 2017 , 40 ( 12 ): 1373 - 1380 . DOI: 10.1007/s40618-017-0723-x http://doi.org/10.1007/s40618-017-0723-x
LIU H K , CHEN W C , LIU Y M , et al . Transarterial embolization in the treatment of 42 patients with low-to-intermediate grade neuroendocrine neoplasm liver metastasis with hypovascular pattern: An analysis of the short-term efficacy and safety [J ] . Chin J Interv Radiol Electron Ed , 2020 , 8 ( 2 ): 130 - 134 .
SHAH M H , GOLDNER W S , BENSON A B , et al . Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 7 ): 839 - 868 . DOI: 10.6004/jnccn.2021.0032 http://doi.org/10.6004/jnccn.2021.0032 https://jnccn.org/view/journals/jnccn/19/7/article-p839.xml https://jnccn.org/view/journals/jnccn/19/7/article-p839.xml
PAVEL M , ÖBERG K , FALCONI M , et al . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2020 , 31 ( 7 ): 844 - 860 . DOI: S0923-7534(20)36394-8 http://doi.org/S0923-7534(20)36394-8
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association . China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition) [J ] . China Oncol , 2022 ( 6 ): 545 - 580 .
FIORI S , DEL GOBBO A , GAUDIOSO G , et al . Hepatic pseudocystic metastasis of well-differentiated ileal neuroendocrine tumor: a case report with review of the literature [J ] . Diagn Pathol , 2013 , 8 : 148 . DOI: 10.1186/1746-1596-8-148 http://doi.org/10.1186/1746-1596-8-148
MORIKAWA K , IGARASHI T , MISUMI S , et al . A case of pseudocystic liver metastases from an atypical lung carcinoid tumor [J ] . Radiol Case Rep , 2019 , 14 ( 5 ): 595 - 601 . DOI: 10.1016/j.radcr.2019.02.022 http://doi.org/10.1016/j.radcr.2019.02.022 https://linkinghub.elsevier.com/retrieve/pii/S1930043319300263 https://linkinghub.elsevier.com/retrieve/pii/S1930043319300263
LI G W , LIANG Z Y , YU X P , et al . The influence of blood supply pattern of hepatic metastases on the short-term effect of TACE [J ] . J Interv Radiol , 2010 , 19 ( 6 ): 493 - 496 .
QIAN L J , ZHU J , ZHUANG Z G , et al . Spectrum of multilocular cystic hepatic lesions: CT and MR imaging findings with pathologic correlation [J ] . Radiographics , 2013 , 33 ( 5 ): 1419 - 1433 . DOI: 10.1148/rg.335125063 http://doi.org/10.1148/rg.335125063
EISENHAUER E A , THERASSE P , BOGAERTS J , et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J ] . Eur J Cancer , 2009 , 45 ( 2 ): 228 - 247 . DOI: 10.1016/j.ejca.2008.10.026 http://doi.org/10.1016/j.ejca.2008.10.026
Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE) version 5.0 [R ] . Bethesda : NIH , 2017 .
PERICLEOUS M , CAPLIN M E , TSOCHATZIS E , et al . Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes [J ] . Asia Pac J Clin Oncol , 2016 , 12 ( 1 ): 61 - 69 . DOI: 10.1111/ajco.12438 http://doi.org/10.1111/ajco.12438 https://onlinelibrary.wiley.com/doi/10.1111/ajco.12438 https://onlinelibrary.wiley.com/doi/10.1111/ajco.12438
DE MESTIER L , ZAPPA M , HENTIC O , et al . Liver transarterial embolizations in metastatic neuroendocrine tumors [J ] . Rev Endocr Metab Disord , 2017 , 18 ( 4 ): 459 - 471 . DOI: 10.1007/s11154-017-9431-2 http://doi.org/10.1007/s11154-017-9431-2 http://link.springer.com/10.1007/s11154-017-9431-2 http://link.springer.com/10.1007/s11154-017-9431-2
RINKE A , MÜLLER H H , SCHADE-BRITTINGER C , et al . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [J ] . J Clin Oncol , 2009 , 27 ( 28 ): 4656 - 4663 . DOI: 10.1200/JCO.2009.22.8510 http://doi.org/10.1200/JCO.2009.22.8510
LIU Y M , LIU H K , CHEN W C , et al . Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden [J ] . Cancer Med , 2022 , 11 ( 13 ): 2588 - 2600 . DOI: 10.1002/cam4.4628 http://doi.org/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628
A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma
Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial
Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor
Related Author
Yilin WANG
Lu WANG
Yang LUO
Tao SUN
Zhimin SHAO
Jiuwei CUI
Yueyin PAN
Qingyuan ZHANG
Related Institution
Department of Liver Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medicine Sciences and Peking Union Medical College
Department of Breast Medicine, Liaoning Provincial Cancer Hospital
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Cancer Center, The First Hospital of Jilin University